{
    "indexed": {
        "date-parts": [
            [
                2025,
                5,
                10
            ]
        ],
        "date-time": "2025-05-10T04:08:25Z",
        "timestamp": 1746850105011,
        "version": "3.40.5"
    },
    "reference-count": 81,
    "publisher": "American Economic Association",
    "issue": "2",
    "content-domain": {
        "domain": [],
        "crossmark-restriction": false
    },
    "short-container-title": [
        "Journal of Economic Perspectives"
    ],
    "published-print": {
        "date-parts": [
            [
                2025,
                5,
                1
            ]
        ]
    },
    "abstract": "<jats:p> A central policy issue in pharmaceuticals is how to balance the dynamic benefits of new drugs against the static benefits of low prices for existing drugs. In the United States, that balance is set by the Hatch-Waxman Act. We review the Act's origins and key features, then present evidence on its effects on competition and innovation. On the competition side, we show how the Act creates incentives for brands to accumulate patents and generics to challenge them, with the result being a rough stalemate. We also discuss strategies deployed by brands to delay generic entry. On the innovation side, we show that the Act's patent extension provisions \u2014 which aim to allow branded firms to make up for time lost during clinical trials and regulatory review \u2014 are incomplete, resulting in potential distortions. The net result is a convoluted and expensive approach to balancing innovation and competition. </jats:p>",
    "DOI": "10.1257/jep.20241423",
    "type": "journal-article",
    "created": {
        "date-parts": [
            [
                2025,
                5,
                9
            ]
        ],
        "date-time": "2025-05-09T13:02:31Z",
        "timestamp": 1746795751000
    },
    "page": "27-52",
    "source": "Crossref",
    "is-referenced-by-count": 0,
    "title": [
        "Patents, Innovation, and Competition in Pharmaceuticals: The Hatch-Waxman Act After 40 Years"
    ],
    "prefix": "10.1257",
    "volume": "39",
    "author": [
        {
            "given": "C. Scott",
            "family": "Hemphill",
            "sequence": "first",
            "affiliation": [
                {
                    "name": "C. Scott Hemphill is the Moses H. Grossman Professor of Law, New York University School of Law, New York City, New York."
                }
            ]
        },
        {
            "given": "Bhaven N.",
            "family": "Sampat",
            "sequence": "additional",
            "affiliation": [
                {
                    "name": "Bhaven N. Sampat is Professor, School for the Future of Innovation in Society and School of Public Affairs, Consortium for Science, Policy and Outcomes Professor, Arizona State University, Washington, DC. He is also a Research Associate, National Bureau of Economic Research, Cambridge, Massachusetts. Sampat is the corresponding author at ."
                }
            ]
        }
    ],
    "member": "11",
    "reference": [
        {
            "key": "p_1",
            "unstructured": "AAM (Association for Accessible Medicines). 2024. The US Generic and Biosimilar Medicines Savings Report. Branstetter, Lee, Chirantan Chatterjee, and Matthew J. Higgins. 2016. \"Regulation and Welfare: Evidence"
        },
        {
            "key": "p_3",
            "unstructured": "(4): 857-90. Brock, Gerald W. 1981. The Telecommunications Industry: The Dynamics of Market Structure. Harvard Univer"
        },
        {
            "key": "p_4",
            "unstructured": "sity Press. Budish, Eric, Benjamin N. Roin, and Heidi Williams. 2015. \"Do Firms Underinvest in Long-Term"
        },
        {
            "key": "p_5",
            "unstructured": "Research? Evidence from Cancer Clinical Trials.\" American Economic Review 105 (7): 2044-85. Bulow, Jeremy. 2004. \"The Gaming of Pharmaceutical Patents.\" Innovation Policy and the Economy 4:"
        },
        {
            "key": "p_6",
            "unstructured": "145-87. Buttorff, Christine, Yifan Xu, and Geoffrey Joyce. 2020. \"Variation in Generic Dispensing Rates in"
        },
        {
            "key": "p_7",
            "unstructured": "Medicare Part D.\" American Journal of Managed Care 26 (11): e355-61. Buxbaum, Jason D., Michael E. Chernew, A. Mark Fendrick, and David M. Cutler. 2020. \"Contribu"
        },
        {
            "issue": "9",
            "key": "p_9",
            "first-page": "1546",
            "volume": "39",
            "year": "1990",
            "journal-title": "Health Affairs"
        },
        {
            "key": "p_10",
            "unstructured": "American University Law Review 66 (2): 305-52. Carrier, Michael A., and Steve Shadowen. 2017. \"Pharmaceutical Product Hopping: A Proposed Frame"
        },
        {
            "key": "p_12",
            "unstructured": "org/do/10.1377/forefront.20170601.060360. Cockburn, Iain, Rebecca Henderson, Luigi Orsenigo, and Gary Pisano. 1999. \"Pharmaceuticals and"
        },
        {
            "key": "p_13",
            "unstructured": "Biotechnology.\" In US Industry in 2000: Studies in Competitive Performance, edited by David C."
        },
        {
            "key": "p_14",
            "unstructured": "Mowery, 363-98. National Academies Press. Cohen, Wesley M., Richard R. Nelson, and John P. Walsh. 2000. \"Protecting Their Intellectual Assets:"
        },
        {
            "key": "p_16",
            "unstructured": "Paper 7552. Conrad, Ryan, and Randall Lutter. 2019. Generic Competition and Drug Prices: New Evidence Linking Greater"
        },
        {
            "key": "p_17",
            "unstructured": "Generic Competition and Lower Generic Drug Prices. US Food and Drug Administration. Contreras, Jorge L., and Arti K. Rai. 2023. \"Orange Book Over-Declaration of Pharmaceutical Patents:"
        },
        {
            "key": "p_19",
            "unstructured": "https://doi.org/10.1377/forefront.20231211.190823. Cutler, David, Angus Deaton, and Adriana Lleras-Muney. 2006. \"The Determinants of Mortality.\" Journal"
        },
        {
            "key": "p_20",
            "unstructured": "of Economic Perspectives 20 (3): 97-120. Danzon, Patricia M., and Michael F. Furukawa. 2011. \"Cross-National Evidence on Generic Pharmaceuti"
        },
        {
            "key": "p_21",
            "unstructured": "cals: Pharmacy vs. Physician-Driven Markets.\" NBER Working Paper 17226. DiMasi, Joseph A., Henry G. Grabowski, and Ronald W. Hansen. 2016. \"Innovation in the Pharmaceu"
        },
        {
            "key": "p_22",
            "unstructured": "tical Industry: New Estimates of R&D Costs.\" Journal of Health Economics 47: 20-33. Durvasula, Maya, C. Scott Hemphill, Lisa Larrimore Ouellette, Bhaven Sampat, and Heidi L. Williams."
        },
        {
            "key": "p_23",
            "doi-asserted-by": "publisher",
            "DOI": "10.1016/j.respol.2023.104791"
        },
        {
            "key": "p_24",
            "unstructured": "trust 28 (1): 16-23. Eisenberg, Rebecca S. 2012. \"Patents and Regulatory Exclusivity.\" In The Oxford Handbook of the Economics"
        },
        {
            "key": "p_25",
            "unstructured": "of the Biopharmaceutical Industry, edited by Patricia M. Danzon and Sean Nicholson, 167-98. Oxford"
        },
        {
            "key": "p_26",
            "unstructured": "University Press. Eisenberg, Rebecca S., and Daniel A. Crane. 2015. \"Patent Punting: How FDA and Antitrust Courts"
        },
        {
            "key": "p_28",
            "unstructured": "and Technology Law Review 21 (2): 197-262. Engelberg, Alfred B. 1999. \"Special Patent Provisions for Pharmaceuticals: Have They Outlived Their"
        },
        {
            "key": "p_29",
            "unstructured": "Usefulness?\" Idea 39 (3): 389. Farrell, Joseph, and Mark Chicu. 2018. \"Pharmaceutical Patents and Pay-for-Delay: Actavis.\" In The"
        },
        {
            "key": "p_31",
            "unstructured": "Lawrence J. White. Oxford University Press. FDA (US Food and Drug Administration). 2023a. Compilation of CDER New Molecular Entity Drug and New"
        },
        {
            "key": "p_33",
            "unstructured": "new-molecular-entity-nme-drug-and-new-biologic-approvals (accessed September 1, 2023). FDA. 2023b. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). https://www."
        },
        {
            "key": "p_35",
            "unstructured": "evaluations-orange-book (accessed September 1, 2023). FDA. 2023c. Patent Certifications and Suitability Petitions. https://www.fda.gov/drugs/abbreviated-new"
        },
        {
            "key": "p_36",
            "unstructured": "drug-application-anda/patent-certifications-and-suitability-petitions (accessed September 1, 2023). FDA. 2023d. Drugs@FDA: FDA-Approved Drugs. https://www.accessdata.fda.gov/scripts/cder/daf/index."
        },
        {
            "key": "p_37",
            "unstructured": "cfm (accessed September 1, 2023). Feldman, William B., Doni Bloomfield, Reed F. Beall, and Aaron S. Kesselheim. 2022. \"Patents and Regu"
        },
        {
            "issue": "6",
            "key": "p_38",
            "first-page": "787",
            "volume": "41",
            "year": "1986",
            "journal-title": "Health Affairs"
        },
        {
            "key": "p_39",
            "unstructured": "Pharmaceutical Patent Examination.\" American Economic Journal: Economic Policy 15 (3): 151-83. FTC (Federal Trade Commission). 2023. \"FTC Challenges More Than 100 Patents as Improperly Listed"
        },
        {
            "key": "p_40",
            "unstructured": "in the FDA's Orange Book.\" Federal Trade Commission (press release), November 7. https://www. ftc.gov/news-events/news/press-releases/2023/11/ftc-challenges-more-100-patents-improperly"
        },
        {
            "key": "p_41",
            "unstructured": "listed-fdas-orange-book. FTC. 2024. \"FTC Expands Patent Listing Challenges, Targeting More Than 300 Junk Listings for"
        },
        {
            "key": "p_42",
            "unstructured": "Diabetes, Weight Loss, Asthma and COPD Drugs.\" Federal Trade Commission (press release), April 30. https://www.ftc.gov/news-events/news/press-releases/2024/04/ftc-expands-patent"
        },
        {
            "key": "p_44",
            "unstructured": "Fendrick. 2014. \"Price Elasticity and Medication Use: Cost Sharing across Multiple Clinical Condi"
        },
        {
            "key": "p_45",
            "unstructured": "tions.\" Journal of Managed Care Pharmacy 20 (11): 1102-07. Gilbert, Richard J., and David M. G. Newbery. 1982. \"Preemptive Patenting and the Persistence of"
        },
        {
            "key": "p_46",
            "unstructured": "Monopoly.\" American Economic Review 72 (3): 514-26. Google Patents Public Data. 2023. Google Patents Public Datasets. https://console.cloud.google.com/"
        },
        {
            "key": "p_48",
            "unstructured": "September 1, 2023. Grabowski, Henry, Carlos Brain, Anna Taub, and Rahul Guha. 2017. \"Pharmaceutical Patent Challenges:"
        },
        {
            "key": "p_49",
            "unstructured": "Company Strategies and Litigation Outcomes.\" American Journal of Health Economics 3 (1): 33-59. Grabowski, Henry G., and Margaret Kyle. 2007. \"Generic Competition and Market Exclusivity Periods in"
        },
        {
            "key": "p_50",
            "unstructured": "Pharmaceuticals.\" Managerial and Decision Economics 28 (4-5): 491-502. Greene, Jeremy A. 2014. Generic: The Unbranding of Modern Medicine. Johns Hopkins University Press. Greene, Jeremy A., and Scott H. Podolsky. 2012. \"Reform, Regulation, and Pharmaceuticals-The"
        },
        {
            "key": "p_51",
            "unstructured": "Kefauver-Harris Amendments at 50.\" New England Journal of Medicine 367 (16): 1481-83. Gross, Daniel P., and Bhaven N. Sampat. 2023. \"The World War II Crisis Innovation Model: What Was It,"
        },
        {
            "key": "p_52",
            "unstructured": "and Where Does It Apply?\" Research Policy 52 (9): 104845. Hemphill, C. Scott. 2006. \"Paying for Delay: Pharmaceutical Patent Settlement as a Regulatory Design"
        },
        {
            "key": "p_53",
            "unstructured": "Problem.\" New York University Law Review 81 (5): 1553-1623. Hemphill, C. Scott. 2009. \"An Aggregate Approach to Antitrust: Using New Data and Rulemaking to"
        },
        {
            "key": "p_54",
            "unstructured": "Preserve Drug Competition.\" Columbia Law Review 109 (4): 629-88. Hemphill, C. Scott, and Mark A. Lemley. 2011. \"Earning Exclusivity: Generic Drug Incentives and the"
        },
        {
            "key": "p_55",
            "unstructured": "Hatch-Waxman Act.\" Antitrust Law Journal 77 (3): 947-89. Hemphill, C. Scott, and Bhaven N. Sampat. 2011. \"When Do Generics Challenge Drug Patents?\" Journal"
        },
        {
            "key": "p_56",
            "unstructured": "of Empirical Legal Studies 8 (4): 613-49. Hemphill, C. Scott, and Bhaven N. Sampat. 2012. \"Evergreening, Patent Challenges, and Effective"
        },
        {
            "key": "p_57",
            "doi-asserted-by": "crossref",
            "unstructured": "Market Life in Pharmaceuticals.\" Journal of Health Economics 31 (2): 327-39. Hemphill, C. Scott, and Bhaven Sampat. 2013. \"Drug Patents at the Supreme Court.\" Science 339 (6126):",
            "DOI": "10.1016/j.jhealeco.2012.01.004"
        },
        {
            "key": "p_58",
            "doi-asserted-by": "crossref",
            "unstructured": "1386-87. Hemphill, C. Scott, and Bhaven N. Sampat. 2022. \"Fixing the FDA's Orange Book.\" Health Affairs 41 (6):",
            "DOI": "10.1377/hlthaff.2022.00369"
        },
        {
            "key": "p_59",
            "unstructured": "797-800. Hemphill, C. Scott, and Bhaven N. Sampat. 2025a. Data and Code for: \"Patents, Innovation, and Competition"
        },
        {
            "key": "p_61",
            "unstructured": "MI. https://doi.org/10.3886/E2184437V1. Hemphill, C. Scott, and Bhaven N. Sampat. 2025b. IND Start Dates Transcribed from Notices of Final Determi"
        },
        {
            "key": "p_62",
            "unstructured": "nation (1985-2023). openICPSR. Version 1. https://doi.org/10.3886/E218443.v1. Hemphill, C. Scott, and Bhaven N. Sampat. 2025c. Additional IND Start Dates Transcribed from the Federal"
        },
        {
            "key": "p_63",
            "unstructured": "Register (1985-2023). openICPSR. Version 1. https://doi.org/10.3886/E218443.v1. Hemphill, C. Scott, and Bhaven N. Sampat. 2025d. Hand-Collected USPTO Patent Reissue Information."
        },
        {
            "key": "p_64",
            "unstructured": "openICPSR. Version 1. https://doi.org/10.3886/E218443.v1. Higgins, Matthew J., and Stuart J. H. Graham. 2009. \"Balancing Innovation and Access: Patent Chal"
        },
        {
            "key": "p_65",
            "unstructured": "lenges Tip the Scales.\" Science 326 (5951): 370-71. IQVIA. n.d. \"ARK Patent Intelligence.\" https://www.iqvia.com/solutions/industry-segments/generics/"
        },
        {
            "key": "p_66",
            "author": "November",
            "year": "2021",
            "journal-title": "Northwestern University Law Review 95"
        },
        {
            "key": "p_67",
            "unstructured": "(4): 1495-1532. Lemley, Mark A., Douglas Lichtman, and Bhaven N. Sampat. 2005. \"What to Do about Bad Patents.\""
        },
        {
            "key": "p_68",
            "unstructured": "Regulation 28 (4): 10-13. Lemley, Mark A., and Bhaven Sampat. 2012. \"Examiner Characteristics and Patent Office Outcomes.\""
        },
        {
            "key": "p_69",
            "doi-asserted-by": "publisher",
            "DOI": "10.1257/0895330054048650"
        },
        {
            "key": "p_70",
            "doi-asserted-by": "crossref",
            "unstructured": "75-98. Levin, Richard C., Alvin K. Klevorick, Richard R. Nelson, and Sidney G. Winter. 1987. \"Appropriating",
            "DOI": "10.2307/2534454"
        },
        {
            "key": "p_72",
            "unstructured": "(3): 783-831. Lichtenberg, Frank R. 2022. \"The Effect of Pharmaceutical Innovation on Longevity: Evidence from the"
        },
        {
            "key": "p_73",
            "unstructured": "U.S. and 26 High-Income Countries.\" Economics and Human Biology 46: 101124. Lietzan, Erika, and Kristina M. L. Acri. 2020. \"Distorted Drug Patents.\" Washington Law Review 95 (3):"
        },
        {
            "key": "p_74",
            "doi-asserted-by": "crossref",
            "unstructured": "1317-82. Mansfield, Edwin. 1986. \"Patents and Innovation: An Empirical Study.\" Management Science 32 (2):",
            "DOI": "10.1287/mnsc.32.2.173"
        },
        {
            "key": "p_75",
            "doi-asserted-by": "crossref",
            "unstructured": "173-81. Mezzanotti, Filippo, and Timothy Simcoe. 2023. \"Innovation and Appropriability: Revisiting the Role of",
            "DOI": "10.3386/w31428"
        },
        {
            "key": "p_76",
            "unstructured": "Intellectual Property.\" NBER Working Paper 31428. NBER. 2023. Orange Book Patent and Exclusivity Data-1985-2016. https://www.nber.org/research/"
        },
        {
            "key": "p_77",
            "unstructured": "data/orange-book-patent-and-exclusivity-data-1985-2016 (accessed September 1, 2023). Office of the Federal Register, National Archives and Records Administration (NARA). 2023. Federal"
        },
        {
            "key": "p_79",
            "unstructured": "2023). Olson, Luke M., and Brett W. Wendling. 2018. \"Estimating the Causal Effect of Entry on Generic Drug"
        },
        {
            "key": "p_80",
            "unstructured": "Prices Using Hatch-Waxman Exclusivity.\" Review of Industrial Organization 53 (1): 139-72. Peltzman, Sam. 1973. \"An Evaluation of Consumer Protection Legislation: The 1962 Drug Amend"
        },
        {
            "key": "p_81",
            "unstructured": "ments.\" Journal of Political Economy 81 (5): 1049-91. Podolsky, Scott H. 2015. The Antibiotic Era: Reform, Resistance, and the Pursuit of a Rational Therapeutics."
        },
        {
            "key": "p_82",
            "unstructured": "Johns Hopkins University Press. Rai, Arti K., Saurabh Vishnubhakat, Jorge Lemus, and Erik Hovenkamp. 2022. \"Post-Grant Adjudication"
        },
        {
            "key": "p_83",
            "unstructured": "of Drug Patents: Agency and/or Court?\" Berkeley Technology Law Journal 37 (1): 139-70. Reddy, Sanjay, Reed F. Beall, S. Sean Tu, Aaron S. Kesselheim, and William B. Feldman. 2023. \"Patent"
        },
        {
            "key": "p_84",
            "doi-asserted-by": "crossref",
            "unstructured": "Challenges and Litigation on Inhalers for Asthma and COPD.\" Health Affairs 42 (3): 398-406. Roin, Benjamin N. 2009. \"Unpatentable Drugs and the Standards of Patentability.\" Texas Law Review 87",
            "DOI": "10.1377/hlthaff.2022.00873"
        },
        {
            "key": "p_85",
            "unstructured": "(3): 503-70. Roin, Benjamin N. 2013. \"The Case for Tailoring Patent Awards Based on Time-to-Market.\" UCLA Law"
        },
        {
            "key": "p_86",
            "unstructured": "Review 61 (3): 672-759. Sampat, Bhaven. 2020. \"Whose Drugs Are These?\" Issues in Science and Technology 36 (4). https://issues."
        },
        {
            "issue": "2",
            "key": "p_87",
            "first-page": "391",
            "volume": "34",
            "author": "Sampat Bhaven",
            "year": "2023",
            "journal-title": "RAND Journal of Economics"
        },
        {
            "key": "p_88",
            "unstructured": "Substitution of Prescription Drugs.\" Health Economics 27 (11): 1717-37. SSR Health. 2024. SSR Health Drug Sales Database (accessed June 25, 2024). Taylor, C. T., and Z. Aubrey Silberston. 1973. The Economic Impact of the Patent System: A Study of the British"
        },
        {
            "key": "p_89",
            "unstructured": "Experience. Cambridge University Press. Temin, Peter. 1979. \"Technology, Regulation, and Market Structure in the Modern Pharmaceutical"
        },
        {
            "key": "p_90",
            "unstructured": "Industry.\" Bell Journal of Economics 10 (2): 429-46. Temin, Peter. 1980. Taking Your Medicine: Drug Regulation in the United States. Harvard University Press. USTPO (US Patent and Trademark Office). 2023a. Patent Examination Data System (PEDS). https://ped."
        },
        {
            "key": "p_91",
            "unstructured": "uspto.gov/peds/# (accessed September 1, 2023). USPTO. 2023b. \"Patent Terms Extended Under 35 U.S.C. \u00a7 156.\" https://www.uspto.gov/patents/laws/"
        },
        {
            "key": "p_92",
            "unstructured": "patent-terms-extended (accessed September 1, 2023). USPTO. 2023c. PatentView. https://www.uspto.gov/ip-policy/economic-research/patentsview. Accessed"
        },
        {
            "key": "p_93",
            "unstructured": "September 1, 2023. Voet, Martin A. 2005. The Generic Challenge: Understanding Patents, FDA and Pharmaceutical Life-Cycle"
        },
        {
            "key": "p_94",
            "unstructured": "Management. 6th ed. BrownWalker Press. Wouters, Olivier J., Martin McKee, and Jeroen Luyten. 2020. \"Estimated Research and Development"
        },
        {
            "issue": "9",
            "key": "p_95",
            "first-page": "844",
            "volume": "323",
            "author": "Market",
            "year": "2009",
            "journal-title": "JAMA"
        }
    ],
    "container-title": [
        "Journal of Economic Perspectives"
    ],
    "original-title": [],
    "language": "en",
    "link": [
        {
            "URL": "https://pubs.aeaweb.org/doi/pdf/10.1257/jep.20241423",
            "content-type": "unspecified",
            "content-version": "vor",
            "intended-application": "similarity-checking"
        }
    ],
    "deposited": {
        "date-parts": [
            [
                2025,
                5,
                9
            ]
        ],
        "date-time": "2025-05-09T13:05:49Z",
        "timestamp": 1746795949000
    },
    "score": 1,
    "resource": {
        "primary": {
            "URL": "https://pubs.aeaweb.org/doi/10.1257/jep.20241423"
        }
    },
    "subtitle": [],
    "short-title": [],
    "issued": {
        "date-parts": [
            [
                2025,
                5,
                1
            ]
        ]
    },
    "references-count": 81,
    "journal-issue": {
        "issue": "2",
        "published-print": {
            "date-parts": [
                [
                    2025,
                    5,
                    1
                ]
            ]
        }
    },
    "alternative-id": [
        "10.1257/jep.20241423"
    ],
    "URL": "https://doi.org/10.1257/jep.20241423",
    "relation": {},
    "ISSN": [
        "0895-3309",
        "1944-7965"
    ],
    "issn-type": [
        {
            "value": "0895-3309",
            "type": "print"
        },
        {
            "value": "1944-7965",
            "type": "electronic"
        }
    ],
    "subject": [],
    "published": {
        "date-parts": [
            [
                2025,
                5,
                1
            ]
        ]
    }
}